Vireo Growth (VREOF) Gross Margin (2020 - 2026)
Vireo Growth (VREOF) posted Gross Margin of 55.84% for Q1 2026, up 2.59% sequentially from 54.43% in Q4 2025, and up 523.0% YoY from 8.96% in Q1 2025.
Vireo Growth (VREOF) Gross Margin (2020 - 2026) Analysis & Trends
Vireo Growth has reported Gross Margin for 7 years, with the latest figure at 55.84% in Q1 2026.
- Quarterly Gross Margin rose 523.0% year-over-year to 55.84% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 49.65% (down 138.0% YoY) and the FY2025 annual result came in at 47.29%, down 380.0% from the prior year.
- Gross Margin improved to 55.84% in Q1 2026 per VREOF's latest filing, from 54.43% in the prior quarter.
- Over five years, Gross Margin peaked at 55.84% in Q1 2026 and troughed at 15.91% in Q1 2022.
- A 5-year average of 47.55% and a median of 49.87% in 2023 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2022 and 2023: Gross Margin sank 2666 bps in 2022, then soared 3396 bps in 2023.
- Over 5 years, Gross Margin stood at 44.72% in 2022, then grew by 12 bps to 49.87% in 2023, then gained by 1 bps to 50.56% in 2024, then increased by 8 bps to 54.43% in 2025, then climbed by 3 bps to 55.84% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 55.84%, 54.43%, and 40.79% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 51.98% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 42.63% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 66.66% |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 87.30% |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 38.77% |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 97.58% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 58.33% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Vireo Growth | 482.88 Mn | 340.58 Mn | 95.30 Mn | 45.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.84% |
| Dec 31, 2025 | 54.43% |
| Sep 30, 2025 | 40.79% |
| Jun 30, 2025 | 42.48% |
| Mar 31, 2025 | 50.61% |
| Dec 31, 2024 | 50.56% |
| Sep 30, 2024 | 48.97% |
| Jun 30, 2024 | 53.97% |
| Mar 31, 2024 | 50.83% |
| Dec 31, 2023 | 49.87% |
| Sep 30, 2023 | 53.48% |
| Jun 30, 2023 | 46.20% |
| Mar 31, 2023 | 49.87% |
| Dec 31, 2022 | 44.72% |
| Sep 30, 2022 | 50.58% |
| Jun 30, 2022 | 49.16% |
| Mar 31, 2022 | 15.91% |
| Dec 31, 2021 | 15.78% |
| Sep 30, 2021 | 38.26% |
| Jun 30, 2021 | 48.58% |